Why the Monitoring Landscape Changed
For years, checking blood sugar in America meant one thing: a fingerstick meter, a lancet, a tiny drop of blood, and a number on a small screen. That routine still works, and it remains the standard for people who test a few times a day. What changed is that continuous glucose monitors, or CGMs, moved from a niche tool for Type 1 patients to mainstream products sold on pharmacy shelves.
The FDA clearance of over-the-counter CGMs reshaped the market. Products like Dexcom Stelo and Abbott's Libre Rio can now be bought without a prescription, opening the door for people with Type 2 diabetes not on insulin, people with prediabetes, and anyone curious about how their meals and workouts move their glucose numbers. A 2025 comparative study of three current-generation CGM systems published in Diabetes Care found meaningful differences in how devices report glucose profiles, which reinforces a practical point: the monitor you choose shapes the data you see, so the choice deserves care.
At the same time, access remains uneven across the country. Rural communities, particularly in states like Mississippi, West Virginia, and Arkansas, still deal with limited pharmacy options and fewer endocrinologists nearby. Telehealth programs backed by the CDC's National Diabetes Prevention Program have closed part of that gap, but the device you can actually buy locally still depends on where you live.
Traditional Meters: Simple, Affordable, Still Essential
The old-fashioned blood glucose meter is not going anywhere, and for good reason. These devices measure glucose directly in your blood and meet FDA standards that require results within 15 percent of a laboratory value 95 percent of the time. For insulin dosing decisions, most clinical guidelines still treat a fingerstick reading as the reference point.
The affordability angle matters more than ever. Walmart's ReliOn line has built a loyal following among people who pay out of pocket, with meters priced well under $20 and test strips that routinely come in under $15 for a 50-count box. OneTouch Verio strips sell for around $31 for a 60-count box at many retailers, and generic options at CVS and Kroger fall in a similar range. For someone testing twice a day, that adds up to a modest monthly expense compared with any CGM.
Accuracy does not suffer with these budget options. Longtime users on pharmacy review boards consistently report that generic strips match brand-name readings within a few points. The trade-offs are practical: you test when you remember, you get a snapshot instead of a trend, and you will not catch overnight lows unless you happen to wake up and test.
Continuous Glucose Monitors: The Trend Data Advantage
A CGM works differently. A tiny sensor sits under the skin and measures glucose in interstitial fluid every one to five minutes, streaming the data to your phone or receiver. That constant feed reveals patterns a fingerstick can never show: the slow climb after a bagel, the dip two hours into a long meeting, the 3 a.m. low that never woke you up.
The accuracy gap between CGMs and fingerstick meters has narrowed considerably. Modern systems like Dexcom G7 and FreeStyle Libre 3 report MARD values around 8 to 9 percent, meaning their readings sit close to lab values most of the time. Still, the interstitial fluid measurement lags behind blood glucose by roughly 5 to 15 minutes, so during rapid changes, like right after a meal or during intense exercise, the numbers can disagree. That is why many clinicians still recommend confirming unusual CGM readings with a fingerstick before making insulin decisions.
Prescription CGMs remain the strongest option for people who need alerts and pump integration. Dexcom G7 warns about predicted lows up to 20 minutes ahead and pairs with automated insulin delivery systems. FreeStyle Libre 3 streams readings automatically with a strong independent accuracy record. The catch is cost: without insurance, Dexcom G7 runs roughly $350 to $400 per month, while Libre 3 Plus lands around $160 per month. Medicare Part B covers CGMs for people who meet specific criteria, typically those using insulin or with a history of problematic lows, and many commercial plans cap patient costs at $20 or less per month.
Over-the-Counter CGMs: The New Middle Ground
The most interesting development for cost-conscious Americans is the OTC CGM category. Dexcom Stelo launched in 2024 as the first FDA-cleared continuous glucose monitor sold without a prescription, and Abbott's Libre Rio followed. These devices target adults 18 and older who do not use insulin and do not have problematic hypoglycemia.
Stelo sells for roughly $89 to $99 for two sensors, each lasting 15 days, which works out to about $99 per month at list price. Libre Rio runs a similar $89 to $99 per month. You can order them directly from the manufacturer or pick them up at Walmart, CVS, Target, or Amazon without a doctor's visit. FSA and HSA funds apply, which softens the financial blow for many buyers.
The trade-offs are real and worth understanding. Stelo only measures glucose in the 70 to 250 mg/dL range, has no high or low alerts, and cannot connect to insulin pumps. That is not a product flaw; it reflects the FDA's clearance scope for wellness-oriented sensors. For someone with prediabetes or well-controlled Type 2 diabetes who wants to understand how food and activity affect their numbers, that is plenty. For someone on insulin, it is the wrong tool.
The table below lays out the main options side by side.
| Device | Prescription Needed | Typical Monthly Cost | Best For | Key Advantages | Main Limitations |
|---|
| Traditional meter (ReliOn, OneTouch) | No | Under $20 for meter; strips roughly $15–$30 per box | Anyone testing 1–4 times daily | Low cost, direct blood measurement, no subscription | Snapshot only, no trends or alerts |
| Dexcom G7 | Yes | $350–$400 without insurance; often under $20 with coverage | Type 1 or insulin-dependent Type 2 | Reads every 5 minutes, predictive low alerts, pump integration | High list price, prescription required |
| FreeStyle Libre 3 Plus | Yes | Around $160 without insurance | Type 2 on insulin wanting accuracy at lower cost | Auto-streaming, 15-day wear, strong accuracy record | Prescription required, no pump integration on all models |
| Dexcom Stelo | No | $89–$99 per month | Type 2 not on insulin, prediabetes, lifestyle tracking | OTC purchase, 15-day wear, FDA-cleared accuracy | No hypo alerts, limited glucose range, no insulin use |
| Abbott Libre Rio | No | $89–$99 per month | Same OTC audience as Stelo | No prescription, pharmacy availability | Same OTC limitations |
Making the Smart Choice for Your Situation
Start with an honest conversation with your care team about how you will use the data. If you manage diabetes with insulin, a prescription CGM with alerts and pump compatibility is the safer path, and Medicare or commercial coverage likely applies. If you test a few times a day and your numbers are stable, a $20 meter with generic strips is hard to beat.
For the wellness track, an OTC CGM makes sense as a short-term experiment. Many people wear one for a month, learn how their glucose responds to specific meals and exercise, and then decide whether the ongoing cost justifies the insight. That approach keeps the expense contained while delivering the trend data that fingersticks simply cannot provide.
Before you buy, check manufacturer savings programs. Dexcom and Abbott both run assistance options for uninsured or underinsured patients that can reduce out-of-pocket costs meaningfully. Pharmacy prices vary by region, so compare your local Walmart, CVS, and independent pharmacies, and ask about membership discounts. For rural residents, mail-order options through the manufacturer or national pharmacy chains often beat local prices.
One more practical tip: whatever device you choose, keep a fingerstick meter as a backup. CGM sensors occasionally fail, and a $15 box of strips is cheap insurance for the days your sensor stops talking to your phone. Sarah, a Texas schoolteacher with Type 2 diabetes not on insulin, wears a Stelo sensor for two weeks each quarter to spot patterns around her lunchtime classroom schedule, then relies on a ReliOn meter the rest of the year. Her annual spending stays manageable, and she says the quarterly data has changed her snack choices more than any nutritionist ever did.
The monitoring market in America now offers a genuine spectrum. Start where your budget and health needs intersect, confirm the numbers you trust, and let the data guide your next step.
研究の知恵